問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

更新時間：2023-09-19

彭忠衎
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

彭忠衎

List

40Cases

2018-12-01 - 2024-12-31

Phase III

Active
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2020-05-12 - 2025-12-31

Phase III

Completed
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (Mermaid-1)

  • Condition/Disease

    Completely Resected Stage II-III NSCLC

  • Test Drug

    Durvalumab Durvalumab

Participate Sites
8Sites

Not yet recruiting6Sites

Recruiting2Sites

2020-07-01 - 2026-06-30

Phase III

Completed
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

  • Condition/Disease

    Eosinophilic Chronic Rhinosinusitis With Nasal Polyps

  • Test Drug

    肺昇朗/Fasenra

Participate Sites
6Sites

Recruiting6Sites

2023-09-01 - 2029-12-31

Phase III

Active
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

  • Condition/Disease

    Metastatic Non-small Cell Lung Cancer

  • Test Drug

    VolrustomigKeytruda Injection

Participate Sites
13Sites

Recruiting13Sites

2022-01-01 - 2031-02-27

Phase III

Active
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Durvalumab Oleclumab Monalizumab

Participate Sites
8Sites

Recruiting8Sites

2024-04-29 - 2027-03-01

Phase II

Active
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

  • Condition/Disease

    Adenocarcinoma of Lung 、Carcinoma, Non-Small-Cell Lung

  • Test Drug

    溶液劑

Participate Sites
5Sites

Recruiting5Sites

2023-02-01 - 2024-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-08-01 - 2024-11-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2021-02-01 - 2026-06-22

Phase III

Active
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Condition/Disease

    Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Test Drug

    Amikacin liposome inhalation suspension (ALIS)

Participate Sites
12Sites

Not yet recruiting6Sites

Recruiting2Sites

Terminated4Sites

2023-06-01 - 2025-06-23

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB